JP2009529541A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529541A5
JP2009529541A5 JP2008558554A JP2008558554A JP2009529541A5 JP 2009529541 A5 JP2009529541 A5 JP 2009529541A5 JP 2008558554 A JP2008558554 A JP 2008558554A JP 2008558554 A JP2008558554 A JP 2008558554A JP 2009529541 A5 JP2009529541 A5 JP 2009529541A5
Authority
JP
Japan
Prior art keywords
group
treatment
prevention
pharmaceutical formulation
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558554A
Other languages
English (en)
Other versions
JP2009529541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063699 external-priority patent/WO2007104053A2/en
Publication of JP2009529541A publication Critical patent/JP2009529541A/ja
Publication of JP2009529541A5 publication Critical patent/JP2009529541A5/ja
Pending legal-status Critical Current

Links

Claims (5)

  1. は、フェニル基、又はメチレンジオキシ基、低級アルキル基、ハロゲン原子、アルキル基、アミノメチル基、アルキルアミノメチル基、ジアルキルアミノメチル基、アシルアミノ基、又はアシルアミノアルキル基で置換されたフェニル基である、請求項2に記載の化合物。
  2. 型糖尿病の予防又は治療用である、請求項19に記載の医薬製剤
  3. 謝障害の予防又は治療用である、請求項19に記載の医薬製剤
  4. 前記障害が肥満である、請求項21に記載の医薬製剤
  5. 食障害、悪液質、糖尿病、変形関節症、胆石、睡眠時無呼吸、神経変性障害、又は癌の予防又は治療用である、請求項19に記載の医薬製剤
JP2008558554A 2006-03-09 2007-03-09 代謝性障害治療のための8−ヘテロアリ−ルプリンのmnk2阻害剤 Pending JP2009529541A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78080006P 2006-03-09 2006-03-09
PCT/US2007/063699 WO2007104053A2 (en) 2006-03-09 2007-03-09 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009529541A JP2009529541A (ja) 2009-08-20
JP2009529541A5 true JP2009529541A5 (ja) 2010-04-30

Family

ID=38371082

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558554A Pending JP2009529541A (ja) 2006-03-09 2007-03-09 代謝性障害治療のための8−ヘテロアリ−ルプリンのmnk2阻害剤

Country Status (12)

Country Link
US (2) US7951803B2 (ja)
EP (1) EP1991547A2 (ja)
JP (1) JP2009529541A (ja)
KR (1) KR20080107466A (ja)
CN (1) CN101454325A (ja)
AU (1) AU2007222982A1 (ja)
BR (1) BRPI0709007A2 (ja)
CA (1) CA2646429A1 (ja)
EA (1) EA014907B1 (ja)
MX (1) MX2008011525A (ja)
WO (1) WO2007104053A2 (ja)
ZA (1) ZA200807715B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
RU2009118963A (ru) * 2006-10-20 2010-11-27 Н.В. Органон (Nl) Пурины в качестве ингибиторов ркс-тета
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GEP20135785B (en) 2008-08-22 2013-03-11 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2011101644A1 (en) 2010-02-18 2011-08-25 Centro Nacional De Investigaciones Oncologicas (Cnio) Triazolo [4, 5 - b] pyridin derivatives
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EA201201191A1 (ru) * 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
EP2917185B1 (en) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
WO2015082324A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
CN105001096B (zh) * 2015-07-21 2017-07-21 沈阳化工研究院有限公司 一种制备4‑氨基‑n‑烷基苄胺的方法
CN106008506B (zh) * 2016-06-27 2018-02-13 山东大学 取代嘌呤类衍生物及其制备方法与应用
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
WO1996031510A1 (en) 1995-04-03 1996-10-10 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors
DE10294485T5 (de) 2001-10-29 2004-04-29 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
US7105526B2 (en) * 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1778224B1 (en) * 2004-07-19 2014-03-26 The Johns-Hopkins University Flt3 inhibitors for immune suppression
ES2508766T3 (es) * 2004-10-29 2014-10-16 Janssen R&D Ireland Derivados de pirimidina bicíclicos que inhiben el VIH
AU2006232105A1 (en) * 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
WO2007035873A1 (en) * 2005-09-21 2007-03-29 Pharmacopeia, Inc. Purinone derivatives for treating neurodegenerative diseases
CA2626623C (en) * 2005-10-18 2016-08-30 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
RU2009118963A (ru) * 2006-10-20 2010-11-27 Н.В. Органон (Nl) Пурины в качестве ингибиторов ркс-тета
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20080220256A1 (en) * 2007-03-09 2008-09-11 Ues, Inc. Methods of coating carbon/carbon composite structures

Similar Documents

Publication Publication Date Title
JP2009529541A5 (ja)
JP2013525444A5 (ja)
JP2017527578A5 (ja)
WO2007131005A3 (en) Use of organic compounds
JP2017526711A5 (ja)
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2012094636A3 (en) Chemosensory receptor ligand-based therapies
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
JP2010518061A5 (ja)
JP2009530399A5 (ja)
JP2013529210A5 (ja)
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
JP2008532974A5 (ja)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
WO2010003624A3 (en) Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
JP2014505107A5 (ja)
JP2012255002A5 (ja)
EP2579876A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDICT
JP2006525297A5 (ja)
JP2016505614A5 (ja)
JP2012507535A5 (ja)
EP2646032A4 (en) THERAPEUTIC TREATMENT OF METABOLIC SYNDROME AND TYPE 2 DIABETES, ADIPOSITAS OR PREDICTES
JP2015516419A5 (ja)
RU2016141650A (ru) Амидные соединения